SLC5A2 and type 2 diabetes mellitus: The CREDENCE trial assessed the impact of a sodium-glucose cotransporter-2 (SGLT2) inhibitor, canagliflozin, on cardiovascular and kidney outcomes in participants with known CKD and type 2 diabetes.